Role of Thymostimulin (TP-1) as an Immunomodulator in Hodgkin’s Disease
With the advent of effective chemotherapy and the introduction of megavoltage radiotherapy techniques, the relapse-free survival (RFS) in previously untreated Hodgkin’s disease has been radically prolonged (Faguet and Davis, 1982). It would appear that the prolonged RFS is, to various degrees, dependent on age, histological subtype, presence of constitutional symptoms, and extent of disease at presentation (Young et al., 1972).
KeywordsSkin Test Reactivity Serum Lysozyme Lysozyme Level Serum Lysozyme Level Migration Inhibitory Activity
Unable to display preview. Download preview PDF.
- Bjorkholm, M., Holm, G., Mellstedt, H., and Johnson, B., 1976, Immunodeficiency and prognosis in Hodgkin’s disease, Acta Med. Scand. 295:1273.Google Scholar
- Falchetti, R., Bergesi, G., and Caprino, L., 1977, Isolation, partial characterization and biological effects of a calf thymus factor, 3rd European Immunology Meeting, Copenhagen.Google Scholar
- Ficher, R., DeVita, V. T., Bostick, F., Vanhaelen, C., Hawsor, D. M., Hubbard, S., and Young, R., 1980, Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin’s disease, Ann. Intern. Med. 92:595–599.Google Scholar
- Reed, D. M., 1902, On the pathological changes in Hodgkin’s disease with respect to the problem of Homotransplantation, Johns Hopkins Hosp. Rep. 10:133.Google Scholar
- Schechtor, G. P., and Soehnlen, F., 1978, Monocyte mediated inhibition of lymphocyte blastogenesis in Hodgkin’s disease, Blood 52:261–271.Google Scholar
- Siegel, F. P., 1976, Inhibition of T-cell rosette formation by Hodgkin’s disease serum, N. Engl. J.Med. 295:1313–1316.Google Scholar